Literature DB >> 12869028

Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides.

D M Klinman1, D Currie.   

Abstract

Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs trigger human PBMC to proliferate and secrete Ig, cytokines and chemokines. CpG ODN have entered clinical trials, and show promise as vaccine adjuvants, antiallergens, and for the treatment of infectious diseases and cancer. ODNs under consideration for human use vary in the sequence, number and location of the CpG motifs they contain. Yet little is known of the magnitude of the immune response elicited by these diverse ODNs, or the rules governing their interaction with immune cells. This work compares the proliferative, IgM, IL-6 and IP-10 response of PBMC from normal donors to a diverse panel of CpG ODNs. Results indicate that ODNs expressing 3-4 different CpG motifs are strongly stimulatory. The location of these motifs is important, with those at the 5' end exerting the greatest influence on ODN activity. These findings provide a basis for the rational design of ODNs optimized for clinical use.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869028      PMCID: PMC1808776          DOI: 10.1046/j.1365-2249.2003.02216.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

Review 1.  From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA.

Authors:  A M Krieg
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2001-06

2.  DNA activates human immune cells through a CpG sequence-dependent manner.

Authors:  M Bauer; K Heeg; H Wagner; G B Lipford
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

3.  Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Authors:  G Hartmann; R D Weeratna; Z K Ballas; P Payette; S Blackwell; I Suparto; W L Rasmussen; M Waldschmidt; D Sajuthi; R H Purcell; H L Davis; A M Krieg
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

4.  Oligodeoxynucleotides containing CpG motifs induce low levels of TNF-alpha in human B lymphocytes: possible adjuvants for Th1 responses.

Authors:  B Bohle; L Orel; D Kraft; C Ebner
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

5.  Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs.

Authors:  A F Carpentier; J Xie; K Mokhtari; J Y Delattre
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

6.  Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Authors:  D Verthelyi; K J Ishii; M Gursel; F Takeshita; D M Klinman
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

7.  Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.

Authors:  A F Carpentier; L Chen; F Maltonti; J Y Delattre
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

8.  Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide.

Authors:  Mayda Gürsel; Daniela Verthelyi; Ihsan Gürsel; Ken J Ishii; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2002-05       Impact factor: 4.962

9.  Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients.

Authors:  B R Blazar; A M Krieg; P A Taylor
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

10.  Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides.

Authors:  Cynthia A Leifer; Daniela Verthelyi; Dennis M Klinman
Journal:  J Immunother       Date:  2003 Jul-Aug       Impact factor: 4.456

View more
  5 in total

1.  CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.

Authors:  Erika Schlaepfer; Annette Audigé; Barbara von Beust; Vania Manolova; Markus Weber; Helene Joller; Martin F Bachmann; Thomas M Kundig; Roberto F Speck
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

2.  Structure-dependent modulation of alpha interferon production by porcine circovirus 2 oligodeoxyribonucleotide and CpG DNAs in porcine peripheral blood mononuclear cells.

Authors:  Frida Hasslung Wikström; Brian M Meehan; Mikael Berg; Sirje Timmusk; Josefine Elving; Lisbeth Fuxler; Mattias Magnusson; Gordon M Allan; Francis McNeilly; Caroline Fossum
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

3.  Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703.

Authors:  Manuel Schmidt; Nicole Hagner; Alberto Marco; Sven A König-Merediz; Matthias Schroff; Burghardt Wittig
Journal:  Nucleic Acid Ther       Date:  2015-03-31       Impact factor: 5.486

Review 4.  CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.198

5.  Broad-spectrum drugs against viral agents.

Authors:  Mary E Christopher; Jonathan P Wong
Journal:  Int J Mol Sci       Date:  2008-09-01       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.